Ocuphire Pharma rises after FDA says it has approved company's eye drug

Opus Genetics

26/09/2023 17:55

** Shares of drug developer Ocuphire Pharma  OCUP.O  rise
8.7% to $4.24
    ** U.S. FDA, as per its website, says it has approved
company's eye drug, Ryzumvi
    ** Ryzumvi is indicated to treat drug-induced mydriasis that
usually occurs during routine eye check-ups, disease monitoring
or surgical procedures
    ** Mydriasis refers to excessive or prolonged dilation of
pupils
    ** Stock up ~22% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com))